AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has recommended for marketing authorization of AstraZeneca Plc's AZN Soliris (eculizumab) for expanded use in refractory generalized myasthenia gravis (gMG) in children and adolescents. gMG is a rare, chronic autoimmune neuromuscular disease causing severe weakness and loss of…#astrazenecaplc #aznsoliris #soliris #qmg #fda #argenxse #argx #vyvgarthytrulo #azn
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: AstraZeneca | Autoimmune Disease | Brain | Children | Health | Marketing | Myasthenia Gravis | Neurology | Pediatrics